Utc Therapeutics (shanghai) Co., Ltd.

Southco, Inc.

Xiaojun Liu

Yangbing Zhao

Bin Li

Jie Wang

Richard B Langkamp, Jr

Wei Pan

Gengzhen Zhu

Jintao Feng

Hailu Wang

Xiaodong Song

Disclosed herein are anti-BCMA antibodies and antigen-binding fragments, chimeric antigen receptors ('CARs') having these anti-BCMA antibodies and antigen-binding fragments (“BCMA CARs”) and genetically modified immune effector cells having such BCMA CARs. Polynucleotides encoding the anti-BCMA antibodies and antigen-binding fragments and BCMA CARs are also provided herein. Compositions comprising anti-BCMA antibodies and antigen-binding fragments and BCMA CARs are also provided herein. The present disclosure also relates to use of the anti-BCMA antibodies and antigen-binding fragments and genetically modified immune effector cells having such BCMA CARs in cancer treatment.

BCMA targetting antibodies, chimeric antigen receptors, and uses thereof

Disclosed herein are anti-mesothelin antibodies and antigen-binding fragments, chimeric antigen receptors ('CARs') having these anti-mesothelin antibodies and antigen-binding fragments (“mesothelin CARs”) and genetically modified immune effector cells having such mesothelin CARs. Polynucleotides encoding the anti-mesothelin antibodies and antigen-binding fragments and mesothelin CARs are also provided herein. Compositions comprising anti-mesothelin antibodies and antigen-binding fragments and mesothelin CARs are also provided herein. The present disclosure also relates to uses of the anti-mesothelin antibodies and antigen-binding fragments and genetically modified immune effector cells having such mesothelin CARs in cancer treatment.

Mesothelin-targetting antibodies, chimeric antigen receptors, and uses thereof

The present application relates to an antigen-binding protein and use thereof, wherein the antigen-binding protein comprises a VH and a VL, wherein the VH comprises an HCDR1, an HCDR2 and an HCDR3, wherein the HCDR1 comprises an amino acid sequence as set forth in SEQ ID NO: 10, the HCDR2 comprises an amino acid sequence as set forth in SEQ ID NO: 12, the HCDR3 comprises an amino acid sequence as set forth in SEQ ID NO: 14; and the VL comprises an LCDR1, an LCDR2 and an LCDR3, wherein the LCDR1 comprises an amino acid sequence as set forth in SEQ ID NO: 2, the LCDR2 comprises an amino acid sequence as set forth in SEQ ID NO: 4, and the LCDR3 comprises an amino acid sequence as set forth in SEQ ID NO: 6. The present application also relates to a pharmaceutical composition comprising the antigen-binding protein and use thereof for the treatment of a cancer.

Antigen-binding protein and use thereof

Disclosed herein are fusion proteins having a first domain that activates an antigen-presenting cell (APC) (e.g., a dendritic cell) by binding to an activation receptor of the APC, and a second domain that activates an immune effector cell (e.g., a T cell) by targeting a co-stimulatory signaling pathway of the immune effector cell, as well as polynucleotides that encode such fusion proteins. Disclosed herein are also genetically engineered immune effector cells expressing such fusion protein, methods of their production, and their uses in treatment of diseases such as cancers.

Lymphocytes-antigen presenting cells co-stimulators and uses thereof

According to one aspect of the invention, a latch is configured to fix a panel relative to a frame. The latch includes a housing configured for engagement to the panel. The latch also includes a cap mounted within the housing and a shaft extending along a longitudinal axis within the housing. A spring of the latch is configured to bias the shaft away from the cap along the longitudinal axis, and a sleeve of the latch interposed between the shaft and the housing, the sleeve defining a first slot. The latch also includes a cam interposed between the shaft and the housing, the cam defining a second slot. A pin is provided which extends into the first and second slots. The first and second slots are configured to guide the rotation and axial movement of the shaft as the cap is rotated within the housing.

Growing community of inventors

Shanghai, China

Xiaojun Liu